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 For peritoneal dialysis to work effi  ciently, 
it is necessary to achieve ultrafi ltration in 
short- to medium-length (2 – 5  h) as well 
as long dialysate dwells; shorter dwell 
cycles require an osmotically active agent, 
so that fl uid can be drawn from the peri-
toneal capillaries via both the water-exclu-
sive aquaporin and the solute-coupled, 
small-pore, fluid pathways. 1 Glucose 
remains the standard osmotic agent used 
to achieve this, especially when higher 
amounts of ultrafi ltration are required. 2 
Alternatives, such as amino acid solutions 
and glycerol, can be used but are limited 
by toxicity (metabolic and lactic acidosis, 
respectively) in the higher concentrations 
needed for greater ultrafiltration vol-
umes. 1 Unfortunately, prolonged use of 
glucose, especially at higher concentra-
tions, is clearly associated with acceleration 
of the progressive changes in membrane 
function that lead to ultrafiltration 
failure. 3 – 5 Th is applies to both increased 
solute transport rates, 3 thought to repre-
sent increased membrane vascularity 
and / or blood fl ow, and the more serious 
reduction in osmotic conductance that is 
likely to result from progressive mem-
brane fi brosis. 5 As a result of these con-
cerns, the search is still on for an eff ective, 
nontoxic osmotic agent that might replace 
or supplement glucose. 
 In this context, the studies by Bonomini 
and colleagues 6 (this issue) describing the 
use of  l -carnitine as an osmotic agent are 
welcome and potentially encouraging. 
Th rough a series of experiments in both 
animal models and peritoneal dialysis 
patients, they set out to show that 
l -carnitine works as anticipated and is 
both safe and biocompatible, and they 
raise the possibility that it might even be 
more eff ective, counterbalancing some of 
the toxic eff ects of glucose. 
 For the fi rst of their claims — that  l -car-
nitine works as an osmotic agent with an 
effi  cacy similar to that of glucose — the 
case is strong. In their rat model of peri-
toneal dialysis, equiosmolar solutions of 
glucose and  l -carnitine resulted in the 
same amount of net ultrafi ltration, which, 
given the closeness in their molecular 
weights, is to be expected. Th ey were also 
able to show by using a mouse knockout 
model for aquaporins (and wild-type con-
trols) that net ultrafi ltration was equiva-
lent, even when the two osmolytes were 
mixed in different proportions, with a 
similar fraction of fl uid removal occurring 
via the aquaporin pathway. In fact, a 
slightly higher proportion of the total 
ultrafiltration (46 versus 35 % ) was via 
aquaporins with the  l -carnitine because 
of less net fluid removal through the 
small-pore pathway, in keeping with its 
slightly lower molecular weight (161.2 
versus 180  Da). Th e smaller an osmolyte 
is, the lower the refl ection coeffi  cient will 
be when it acts across the small pores, 
resulting in less effi  cient ultrafi ltration via 
this pathway, whereas for the water-exclu-
sive aquaporin pathway, all osmolytes will 
have the same effi  ciency, as the refl ection 
coeffi  cient equals unity ( Figure 1 ). When 
 l -carnitine was given to four patients on 
peritoneal dialysis in the form of a long-
dwell solution made as a glucose / l -carni-
tine mix with a combined osmolality close 
to glucose 2.5 % , the observed ultrafi ltra-
tion was equivalent or possibly better over 
a 5-day period of exposure. 
 In addition to effi  cacy, Bonomini and 
colleagues 6 evaluated the safety and basic 
pharmacokinetics of  l -carnitine in their 
four patients exposed for 5 consecutive 
days to the 1.5 % glucose plus 0.25 % 
 l - carnitine mixture. None of the patients 
studied experienced any side effects or 
adverse events. There was, as would be 
anticipated, a signifi cant increase in the 
plasma concentrations of  l -carnitine and 
its metabolite acetyl-carnitine; unfortu-
nately, the 5 days of exposure was not suf-
fi cient to reach a steady state, although it is 
clear from the data presented that this can 
be reached provided administration is con-
fi ned to a single dwell per day, thus enabling 
the  l -carnitine to be excreted during the 
remaining glucose-based exchanges and 
via the urine if present. Whether this fi nal 
plasma concentration, likely to be in the 
region of 1.7 – 2.0  mmol / l on the basis of 
extrapolation of the presented data, is safe 
in the long term is not certain, and further 
safety studies will be required. Experience 
of prolonged  intravenous administration of 
 L -Carnitine: more than just 
an alternative to glucose 
as an osmotic agent for 
peritoneal dialysis ? 
 Simon J.  Davies 1 , 2 
 Glucose toxicity remains a concern for long-term membrane function 
and metabolic side effects in peritoneal dialysis. Partial substitution of 
 L -carnitine as an alternative but similarly effective osmotic agent is an 
attractive proposition, and, given once daily with glucose, it achieves 
equivalent ultrafiltration and plasma concentrations that are likely to be 
safe. The possibility that it can counter glucose-mediated injury to the 
aquaporin pathway, thus enhancing ultrafiltration, is an intriguing 
bonus that requires further study. 
 Kidney International (2011)  80, 565 – 566.  doi: 10.1038/ki.2011.171 
 1 Institute for Science and Technology in Medicine, 
Keele University ,  Keele ,  Staffordshire ,  UK and  
 2 Department of Renal Medicine, University 
Hospital of North Staffordshire ,  Stoke-on-Trent , 
 Staffordshire ,  UK  
 Correspondence: Simon J. Davies, Department 
of Renal Medicine, University Hospital of 
North Staffordshire, Prince ’ s Road, Hartshill, 
Stoke-on-Trent, ST4 7LN, UK. E-mail:  simondavies1@
compuserve.com or  simonj.davies@uhns.nhs.uk 
see original article on page 645
commentar y
566   Kidney International (2011) 80
high doses of carnitine (up to 40  mg / kg 
three times per week) to hemodialysis 
patients would suggest that the dose used 
here (probably more, in fact — for example, 
 ~ 60  mg / kg daily) will be safe, 7 but confi r-
mation is essential. 
 Bonomini  et al. 6 also suggest that the 
observed effi  cacy of their glucose / l -carni-
tine mix is a little higher than might be 
predicted. Th ey observed that over the 5 
days of exposure, especially aft er the fi rst 
1 or 2 days, the amount of ultrafi ltration 
obtained appeared to increase — despite 
the fact that their mixed solution has an 
overall osmolality that is a little less than 
that of the preceding  ‘ control ’ solution of 
glucose 2.5 % . Given the very small num-
bers of patients and the day-to-day varia-
bility usually observed in drain volumes, 
the validity of this observation has to be 
assessed with extreme caution. However, 
assuming it is real, what could the explana-
tions be? One possibility is that  l -carnitine 
alters the solute-transport-rate character-
istics of the peritoneal membrane over a 
few days by causing some vasoconstriction 
of the peritoneal vessels, resulting in pres-
ervation of the osmotic gradient. To test 
for this it will be necessary to perform 
repeated membrane-function tests aft er a 
few days ’ exposure. It is also not clear how 
the increase in plasma  l -carnitine aff ects 
plasma osmolality during the course of an 
exchange. It would be helpful, when 
undertaking these repeated membrane-
function tests, to measure plasma and dia-
lysate osmolality during the course of the 
exchanges to see whether the osmotic gra-
dient is better maintained aft er a few days 
of exposure. Finally, the authors postulate 
that exposure of the peritoneal membrane 
to  l -carnitine might lead to an increase in 
the endothelial expression and function of 
aquaporins, leading to enhanced free water 
transport across the membrane and thus 
better ultrafi ltration. To support this sug-
gestion, they present data on the  in vitro 
expression of aquaporin-1 by cultured 
human umbilical vein endothelial cells. 
Glucose suppressed aquaporin expression, 
whereas the addition of  l -carnitine pre-
vented this. A similar benefi cial interac-
tion was seen with regard to cell viability. 
Again, this potential mechanism requires 
further investigation in the  in vivo setting, 
which would be quite easily achieved by 
measurement of the changes in ultrafi ltra-
tion occurring via the aquaporin and 
small-pore pathways, respectively, during 
membrane-function tests performed 
before and aft er the  l -carnitine exposure. 
To support their findings the authors 
would need to demonstrate that there was 
an absolute increase in the free water ultra-
fi ltration rather than just a change in the 
proportion occurring via the two pathways 
as observed in their short-term mouse 
experiments. 
 Even if ultimately  l -carnitine does not 
increase ultrafi ltration in a clinically sig-
nifi cant way, it is still attractive to use an 
agent that might reverse the local toxic 
eff ects of glucose and enable an overall 
reduction in glucose exposure systemi-
cally. Indeed, in future clinical trials it 
might well be easier to demonstrate the 
systemic metabolic benefi ts (especially if 
carnitine has other eff ects, as previously 
claimed 7 ) or improved management of 
fl uid status than to demonstrate the local 
membrane biocompatibility advantages. 
The requirement of very long trials of 
large numbers of patients (needed to 
account for subsequent dropout) has 
bedeviled attempts to generate high-qual-
ity evidence in terms of strong clinical end 
points for solutions designed to improve 
biocompatibility. In developing further 
evidence on the safety and efficacy of 
 l -carnitine-containing solutions, which 
seems well worthwhile on the basis of the 
evidence presented, the investigators will 
need to take these limitations and poten-
tial benefi ts into account. 
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 Figure 1  |  Relative proportion of fluid transport via pathways across the peritoneal 
membrane. The three-pore model predicts that approximately 60 % of the ultrafiltration achieved 
with glucose will travel through the small intercellular pores, and 40 % via the transcellular 
aquaporins. Substituting  L -carnitine, the proportions are likely to be similar, given the closeness of 
their molecular weight. Given that  L -carnitine is slightly smaller than glucose, it would be expected 
that ultrafiltration would be a little less via this pathway but identical across the aquaporins, where 
the reflection coefficient for all solutes will be 1.0, assuming that the solutions are equiosmolar. 
